CorMedix Inc. CRMD R2K

Q: What is the current share price of CorMedix Inc. (CRMD)?

As of 2026-07-14 21:23 PDT, CorMedix Inc. (CRMD) trades at $8.27 on NasdaqGM. Its 52-week range is $6.25 to $14.83.

Q: What is the market capitalisation of CRMD?

CorMedix Inc. (CRMD) has a market capitalisation of $648.80M on NasdaqGM.

Q: What is the P/E ratio of CRMD?

CRMD trades at a trailing price-to-earnings (P/E) ratio of 3.81. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.57.

Q: What is the return on equity (ROE) of CRMD?

CRMD has a return on equity (ROE) of 65.59%. Its return on capital employed (ROCE) is 23.03%.

Q: Is CRMD a good stock to buy?

This page provides a data-driven analysis of CorMedix Inc. (CRMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://cormedix.com

Company Profile ↓

$8.27

-27.20% 1Y

Mkt Cap$648.80M

P/E3.81

P/B1.57

52W High$14.83

52W Low$6.25

Book Value$5.58

EPS (TTM)$2.17

Company Overview

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 65.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 23.0%.

Steady Revenue Expansion

Revenue has grown at a 305.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 3.8, below the sector median of 25.4.

Healthy Margins

Maintains a net profit margin of 45.2%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.34.

Recent Developments

Dec 2025 Revenue of $311.71M (+617.0% YoY); net profit $163.06M.
Trailing 12 Months Year-on-year growth — revenue +226.1%, earnings +42.8%.
5-Year Trend Long-term compounding — revenue CAGR 305.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	305.80%
1 Year:	226.10%

Compounded Profit Growth

5 Years:	-
1 Year:	42.80%

Stock Price Performance

1 Year:	-27.20%
6 Months:	+8.39%
3 Months:	+12.98%
1 Month:	-7.70%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 24% of range

$6.25 $14.83

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)47.21 · Neutral

Price Performance

1M-7.70%

3M+12.98%

6M+8.39%

1Y-27.20%

Valuation vs Sector

P/E of 3.81 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 65.6%.
Healthy ROCE of 23.0%.
Excellent profit margin of 45.2%.
Compounding revenue at 305.8% over 5 years.
Generates positive free cash flow.

CONS

Trading 44.2% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

3.81

Industry PE

25.41

Forward P/E

23.63

PEG Ratio

Book Value

$5.58

Price to Book

1.57

P/S

1.71

EV/EBITDA

2.86

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

305.80%

Profit 5Y

Revenue (YoY)

226.10%

Earnings (YoY)

42.80%

Profitability & Returns

ROCE

23.03%

ROE

65.59%

ROA

26.40%

Profit Margin

45.25%

Op Margin

49.96%

Gross Margin

91.86%

EPS (Latest Qtr)

$0.43

EPS (TTM)

$2.17

Balance Sheet & Liquidity

Debt/Equity

0.34

Quick Ratio

2.58

Current Ratio

2.98

Debt

$147.42M

Total Assets

$815.64M

Current Assets

Working Capital

Ownership

Promoter Holding

7.53%

Chg in Prom Hold

0.02%

FII / Inst Holding

54.72%

Chg in FII Hold

-0.29%

Financial Snapshot

Enterprise Value

$648.80M

Total Revenue (TTM)

$400.05M

EBITDA

$228.80M

Free Cash Flow

$119.84M

Operating Cash Flow

$197.69M

Shares Outstanding

78.45M

Gross Margin

91.86%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CRMD CorMedix Inc. R2K	8.27	3.81	$648.80M	0.00%	23.03%	65.59%	305.80%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.08M	-	-	127.43M
Gross Profit	0	-68.82K	-14.75K	15.77K	14	18	1	-141	-8.80K	-170.68K	529	36	-54.01K	118.12K	-5.58K	-5.37K	-26.11K	60.08K	-63.26K	14.14K	-19.50K	25.54K	-2.74K	13.11K	26.92K	-6.24K	12.92K	6.11K	20.92K	5.35K	-	-	-	-818.54K	296.28K	10.77M	37.48M	37.87M	93.08M	105.12M
Operating Income	-1.26M	-2.93M	-1.89M	-1.86M	-3.91K	-4.13K	-4.71K	-3.89K	-4.15M	-4.91M	-9.16M	-6.43K	-7.62M	-7.02M	-8.01M	-10.19M	-8.57M	-10.24M	-4.92M	-5.54M	-5.17M	-5.61M	-8.92M	-6.60M	-7.21M	-5.88M	-8.56M	-7.03M	-8.24M	-6.96M	-11.02M	-11.80M	-10.47M	-16.70M	-15.30M	-3.29M	20.12M	19.54M	51.35M	63.66M
Net Income	-2.50M	-16.71M	3.51M	-5.04M	-5.50K	-4.13K	-4.69K	-3.87K	-4.12M	-4.89M	-9.13M	-6.40K	-7.60M	-5.15M	-9.96M	-10.19M	-8.56M	-10.24M	-5.17M	-696.16K	-5.26M	-5.56M	-3.78M	-6.60M	-7.22M	-4.63M	-8.57M	-7.03M	-7.60M	-6.85M	-10.57M	-11.27M	-9.74M	-14.47M	-14.15M	-2.78M	20.64M	19.83M	108.56M	38.60M
Diluted EPS	-	-	-0.05	-	-	-0.13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.22	-0.18	-0.19	-0.17	-0.24	-0.25	-0.17	-0.25	-0.25	-0.05	0.30	0.28	1.26	0.43
R&D Expense	750.77K	353.02K	171.93K	292.69K	1.24K	1.80K	1.76K	1.49K	2.09M	2.77M	6.84M	4.03K	4.92M	5.09M	6.01M	8.28M	6.60M	8.29M	2.87M	2.98M	2.52M	2.47M	5.69M	2.93M	2.64M	2.52M	4.74M	2.29M	3.21M	2.34M	3.41M	4.79M	2.66M	837.45K	650.99K	727.12K	3.19M	2.44M	5.10M	7.21M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	0	2.00K	189.27K	210.13K	224.10K	329.33K	429.80K	283.27K	239.23K	190.94K	65.41K	-	43.47M	311.71M
Gross Profit	-	-	-	-	-	0	-199.60K	-256.52K	-108.59K	-142.57K	214.36K	33.01K	-89.97K	34.38K	42.00K	61.67K	-	40.28M	275.75M
Operating Income	-	-	-	-8.51M	-7.25M	-3.00M	-4.92M	-8.90M	-16.65M	-24.76M	-32.92M	-26.86M	-21.01M	-27.22M	-29.44M	-30.62M	-48.96M	-22.36M	150.14M
Net Income	-7.24M	-9.00M	-8.12M	-10.91M	-6.71M	-3.38M	-9.13M	-20.45M	-18.19M	-24.64M	-33.01M	-26.83M	-16.43M	-22.03M	-28.21M	-29.70M	-46.34M	-17.93M	163.06M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.75	-0.74	-0.91	-0.30	2.04
R&D Expense	-	-	-	5.49M	4.10M	1.14M	1.23M	1.32M	6.28M	15.74M	24.49M	18.82M	11.05M	13.38M	13.13M	10.68M	13.16M	3.94M	19.33M

Balance Sheet (Annual)

Figures in USD.

Metric	Jul 2006	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	8.85M	2.56M	1.15M	2.97M	5.10M	37.10M	21.91M	13.45M	18.83M	29.48M	49.31M	68.95M	62.04M	82.06M	118.85M	826.14M
Total Equity	-	-966.17K	-4.40M	-12.03M	-14.71M	7.26M	1.24M	-335.38K	-4.02M	3.63M	34.01M	17.81M	7.19M	4.93M	23.65M	44.22M	62.80M	55.06M	70.14M	84.66M	405.31M
Cash & Equivalents	0	-	-	-	1.51M	8.28M	1.99M	835.47K	2.37M	4.34M	11.82M	8.06M	10.38M	17.62M	16.35M	41.91M	53.32M	43.15M	43.64M	40.65M	144.84M
Total Liabilities	-	-	-	-	-	1.59M	1.32M	1.49M	6.99M	1.46M	3.09M	4.09M	6.26M	13.89M	5.83M	5.09M	6.15M	6.98M	11.92M	34.19M	420.83M
Current Liabilities	-	-	-	-	-	1.58M	1.31M	1.48M	1.67M	1.43M	3.06M	4.09M	6.26M	7.77M	5.83M	4.16M	5.35M	6.31M	11.40M	33.84M	174.27M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-3.67M	-6.30M	-2.28M	-3.62M	-6.32M	-12.53M	-22.27M	-28.59M	-23.70M	-15.05M	-21.97M	-21.16M	-24.36M	-38.41M	-50.62M	175.05M
Investing Cash Flow	-10.36K	-1.62K	0	-35.68K	-25.40K	-23.61M	11.42M	10.36M	1.56M	-12.02M	7.43M	-9.13M	-3.71M	-17.06M	21.23M	-308.43M
Financing Cash Flow	10.46M	0	1.13M	5.20M	8.36M	43.63M	7.09M	20.52M	29.40M	25.80M	40.10M	41.76M	17.90M	55.92M	26.32M	238.45M
Capital Expenditure	-10.36K	-1.62K	-0	-35.68K	-25.40K	-15.45K	-58.72K	-151.99K	-48.89K	-36.57K	-112.64K	-1.43M	-219.36K	-327.30K	-116.00K	-2.26M
Free Cash Flow	-3.68M	-6.30M	-2.28M	-3.65M	-6.35M	-12.54M	-22.32M	-28.74M	-23.75M	-15.09M	-22.08M	-22.58M	-24.58M	-38.74M	-50.73M	172.79M

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-9,975.2%	-135.5%	-51.7%	-63.6%	65.1%	7.7%	-31.8%	14.4%	22.0%	94.3%	-	92.7%	88.5%
Operating Margin %	-	-	-	-	-	-	-245,646.9%	-4,703.3%	-7,925.6%	-11,048.8%	-9,997.4%	-6,250.4%	-7,416.3%	-11,378.4%	-15,417.5%	-46,819.9%	-	-51.4%	48.2%
Net Margin %	-	-	-	-	-	-	-456,426.7%	-10,806.3%	-8,655.4%	-10,996.5%	-10,023.4%	-6,242.4%	-5,801.3%	-9,207.7%	-14,774.7%	-45,409.9%	-	-41.2%	52.3%
ROE %	164.6%	74.8%	55.2%	-150.3%	-542.8%	1,008.0%	227.1%	-562.8%	-53.5%	-138.3%	-458.9%	-543.7%	-69.5%	-49.8%	-44.9%	-53.9%	-66.1%	-21.2%	40.2%
ROCE %	-	-	-	-117.0%	-579.3%	928.2%	-379.9%	-242.4%	-48.9%	-139.0%	-457.7%	-242.9%	-88.8%	-60.3%	-46.3%	-55.0%	-69.3%	-26.3%	23.0%

Shareholding Pattern

Insiders

7.53%

Institutions

54.72%

Public Float

59.18%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Deep Track Capital, Lp	8.00%	6.27M	$55.02M
2	Blackrock Inc.	7.61%	5.97M	$52.34M
3	Vanguard Capital Management LLC	3.99%	3.13M	$27.45M
4	State Street Corporation	2.79%	2.19M	$19.22M
5	Royce & Associates LP	2.41%	1.89M	$16.55M
6	Geode Capital Management, LLC	2.32%	1.82M	$15.93M
7	UBS Group AG	1.96%	1.54M	$13.49M
8	Oberweis Asset Management Inc.	1.54%	1.21M	$10.62M
9	Alyeska Investment Group, L.p.	1.08%	850.00K	$7.45M
10	Vanguard Portfolio Management LLC	0.95%	742.57K	$6.51M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CRMD

Google News Wed, 17 Jun 2026

CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxObXA4VWJCWnRUZHgtUUE4bzBMRGRRaW9MZzd0Nnh5RzhkNnJJNGY5NXZCUGhWSEVTOURvejA3SGoxanhqMVE1VDJSYlZEcHRjcVp1WFhJTnlrZDZ6NXkyN2lSbU5NREd6enVzZDdCalhDakQyNmN4VG1XWHVvQ0NNRmJLOWpUYkE0akxnN1…

Google News hu, 05 Mar 2026

Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQcEZIdHpiQUt5bFZUVWY1V0JFckR2c0xVblBsMUZtNmxqX2l1OXlWSG9HSG1IRWhZYzU5TmM0U1dPaVBQMzNvZExsOVFaWGk2RGgtTzc2blhrYXNQd3NDcnpwWVRGaHh0a0k1eGFpeU1QalhVazdqZHl6VHlwVUVsQTM2dVJNdk5vZXA2Xz…

Google News Mon, 13 Jul 2026

Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD - TradingView

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNSFY2dEQ1TTVURXJ1VFJnT2dNVGljVkh6dGpoNDJxZ2J0QzhGR0pERkxWWEpsZk5vcEpabFZMakw4QjR3Z09GTkc0VDh2czJkZ0E3NjFGc2FUNGlsX0xFOW91M3Rsc3plRkNIMXM2cEx0aWpLaDZGQldwVkJMRXlqUGY2cjJNME10SEdSWH…

Google News Mon, 13 Jul 2026

(CRMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPQVNMNXZoaWV6N1gyMzlMZ2ZESElmcEJJQWZfQUlhUS1EeGNQZ3R2dE5mQWplc1p3RVMtZEZGNGkybVp1aEVCdERzcHJNdy1HdndFUURTYk9IOEtlSENtMEhEakZPLTQySUc0S3c3QjFnd3JQWG1MZTNOVGJDalBXYk5kMjJOVUY0VFJxbn…

Google News Wed, 24 Jun 2026

CorMedix (CRMD) shareholders affirm directors but vote down multiple charter amendments - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPOFJPd05pNUVqSHRuS2t5dmt6QUtHV2hzMEhDQVhCRGM2eERLQVRBeHFtcC1rRWp2U2hMcXYxV3I5UndlZXRhbUl4U0hXUzMwQnFndW5JOVJ5aDRfQmFYSWdhd01fR2xud3psejJ6R2JXZWVIdEU2QWt6OG9YdGJPbnJETHJkQnk3UFJ4Yj…

Google News ue, 30 Jun 2026

CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNejJ3SlFaNVNxMzlqbjhzSUIzSmcyNVJKS3lyenpjSEpuZHI3TWxBVzY2VmFETENwRzdSYnh4Q0x0OTFhOFRuYV96QVM3ZUhVQWlXYmhEbHdjOVNZM1hmVGxYOFM1MkhfY3RsWEY3NmFHanRGNHp6OElLZ09aMFJCT3dZaFF0V1VPOHVmOD…

CRMD — Frequently Asked Questions

What is the current share price of CorMedix Inc. (CRMD)?

As of 2026-07-14 21:23 PDT, CorMedix Inc. (CRMD) trades at $8.27 on NasdaqGM. Its 52-week range is $6.25 to $14.83.

What is the market capitalisation of CRMD?

CorMedix Inc. (CRMD) has a market capitalisation of $648.80M on NasdaqGM.

What is the P/E ratio of CRMD?

CRMD trades at a trailing price-to-earnings (P/E) ratio of 3.81. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.57.

What is the return on equity (ROE) of CRMD?

CRMD has a return on equity (ROE) of 65.59%. Its return on capital employed (ROCE) is 23.03%.

Is CRMD a good stock to buy?

This page provides a data-driven analysis of CorMedix Inc. (CRMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

CorMedix Inc. CRMD R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook - Yahoo Finance

Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits

Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD - TradingView

(CRMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily

CorMedix (CRMD) shareholders affirm directors but vote down multiple charter amendments - Stock Titan

CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path - Yahoo Finance

CRMD — Frequently Asked Questions

What is the current share price of CorMedix Inc. (CRMD)?

What is the market capitalisation of CRMD?

What is the P/E ratio of CRMD?

What is the return on equity (ROE) of CRMD?

Is CRMD a good stock to buy?

Explore More